Recruitment at the
Rosalind & Morris
Goodman Cancer Institute
The Rosalind and Morris Goodman Cancer Instittue (GCI) is dedicated to shaping the future of cancer research by recruiting exceptional graduate students from across Canada and beyond. Our Annual Recruitment Event is a key part of this mission, connecting aspiring researchers with the institute's vibrant academic community.
Through the Annual Graduate Recruitment Event, we offer top applicants a unique chance to visit the institute, meet current graduate students and faculty, and learn about cutting-edge research opporunities.
Applications for 2026
are now open
Are you interested in pursuing graduate studies in cancer research with us?
Apply to attend our annual Graduate Student Recruitment Event for a unique opportunity to explore the GCI and learn about our cutting-edge research and scientific platforms.
Top applicants will be invited to attend the event that aims to be both informative and convivial. We will introduce the GCI’s extensive training program and provide an opportunity to meet with existing graduate students and cancer scientists.
Selected invitees will then be offered a scholarship for Fall 2026 or Winter 2027 admission. Please note that all travel expenses will be covered for invited students unless specified otherwise.
The deadline to apply is December 1st, 2025.
Join us for a live information session to ask questions and learn more about the program. More details regarding day and time of the information session will be added soon. Check back to sign up!
Interested candidates must complete an online registration form HERE.
Within the online registration form, applicants will be asked to upload the following information in 1 single pdf:
- An up-to-date CV with valid contact information
- A letter of intent (maximum 2 pages) and
- A copy of your most recent transcripts (these do not need to be official for the purpose of this event)
Registration is open
Deadline to submit an application
December 1st, 2024
In-person Events
January 23rd - 24th 2025
- Demonstrated interest in biomedical research
- Enrolled in a B.Sc. or M.Sc. program
- GPA of 3.6 out of 4.3 for M.Sc. & Ph.D. candidates; international students will be evaluated on individual basis.
The GCI is committed to equity and diversity in the recruitment of its trainees. We welcome and encourage applications from racialized persons/visible minorities, women, Indigenous persons, persons with disabilities, ethnic minorities, and persons of minority sexual orientations and gender identities as well as others who may contribute to diversification.
The following investigators are recruiting new students:
Dr. Zogopoulos’ lab studies the genetics and oncogenomics of pancreaticobiliary cancers. His research includes discovery of genetic associations with familial pancreatic cancer, and therapeutic opportunities for pancreaticobiliary cancers driven by homologous recombination deficiency.
To pursue his research interests, Dr. Zogopoulos established and directs the Quebec Pancreas Cancer Study (QPCS), a familial patient registry and biospecimen repository for pancreatic, biliary tract and peri-ampullary malignancies. His program’s resources also include patient-derived tumour xenograft and cell-line libraries.
His translational research program is integrated into the ambulatory oncology clinics at the McGill University Health Centre to facilitate access to genetic counseling and testing as well as precision oncology and early detection opportunities for patients with pancreaticobiliary cancers.
Dr. Zogopoulos is the Pancreatic Disease Oriented Group co-Chair of the Canadian Cancer Trials Group (CCTG), and his research activities also include the pan-Canadian Pancreatic Cancer Profiling for Individualized Care (EPPIC) study, the Quebec Consortium for Novel Cancer Therapeutics and Biomarkers, the Pancreatic Cancer Genetic Epidemiology (PACGENE) consortium, and the Pancreatic Cancer Early Detection (PRECEDE) consortium.
His clinical practice focuses on the surgical treatment of pancreatic, biliary and hepatic malignancies, as well as abdominal organ transplantation with a focus on transplant oncology.
What we are
currently
working on
Pancreatic and biliary tract cancers are difficult-to-treat diseases with poor survival rates. To improve these outcomes, we built a precision health program with Canadian and international collaborations. These research networks bring innovative, point-of-care research opportunities to patients and families affected by these cancers. Our bench-to-bedside research is focused on high-content genomics, preclinical drug testing models, screening of high-risk individuals, and biomarker development.
Our program’s research activities have included implementing point-of-care germline testing for patients with pancreatic cancer, starting a surveillance program for individuals at high-risk for pancreatic cancer, the pan-Canadian Pancreatic Cancer Profiling for Individualized Care (EPPIC) study and its Comprehensive Molecular Characterization of Advanced PC trial (COMPASS, NCT02750657), the Quebec Cancer Consortium (QCC), the Comprehensive Molecular Profiling of Advanced Biliary Tract Cancers trial (COMPASS-B, NCT04318834), the Marathon of Hope Cancer Centres Network (MOHCCN), the Pancreatic Cancer Genetic Epidemiology consortium (PACGENE), the Pancreatic Cancer Early Detection consortium (PRECEDE, NCT04970056), and the Canadian Strategy for Personalized Management of Pancreatic Cancer (Casper-PANC).
Our program’s research activities have included implementing point-of-care germline testing for patients with pancreatic cancer, starting a surveillance program for individuals at high-risk for pancreatic cancer, the pan-Canadian Pancreatic Cancer Profiling for Individualized Care (EPPIC) study and its Comprehensive Molecular Characterization of Advanced PC trial (COMPASS, NCT02750657), the Quebec Cancer Consortium (QCC), the Comprehensive Molecular Profiling of Advanced Biliary Tract Cancers trial (COMPASS-B, NCT04318834), the Marathon of Hope Cancer Centres Network (MOHCCN), the Pancreatic Cancer Genetic Epidemiology consortium (PACGENE), the Pancreatic Cancer Early Detection consortium (PRECEDE, NCT04970056), and the Canadian Strategy for Personalized Management of Pancreatic Cancer (Casper-PANC).
- Détection précoce et interception du cancer du pancréas L'objectif de ce programme clinique et de recherche intégré est la détection précoce et l'interception des changements précancéreux et cancéreux dans le pancréas. Le programme intègre la recommandation clinique selon laquelle les personnes présentant un risque élevé de cancer du pancréas doivent subir une surveillance clinique dans un cadre de recherche. En 2013, l'EQCP a été élargie pour offrir une surveillance du cancer du pancréas aux individus à haut risque au Québec. Le programme est le premier du genre au Québec, le plus grand au Canada, et un site fondateur du Consortium de Détection Précoce du Cancer du Pancréas (PRECEDE) (lien ici). PRECEDE est un groupe collaboratif international et multi-institutionnel travaillant à accroître la survie du cancer du pancréas en améliorant la détection précoce et la prévention.
Comment participer
Cette étude est ouverte aux inscriptions. Pour participer, veuillez contacter l'équipe de l'étude en utilisant le bouton "Nous contacter" ci-dessous.
ClinicalTrials.gov ID: NCT04970056 Pancreatic Cancer Early Detection and Interception The goal of this integrated clinical and research program is early detection and interception of precancerous and cancerous changes in the pancreas. The program incorporates the clinical recommendation that individuals at high risk for pancreatic cancer undergo clinical surveillance in a research setting. In 2013, the QPCS was expanded to offer pancreatic cancer surveillance to high-risk individuals in Quebec. The program is the first of its kind in Quebec, the largest in Canada, and a founding site of the Pancreatic Cancer Early Detection (PRECEDE) Consortium (link here). PRECEDE is an international, multi-institutional collaborative group working to increase pancreatic cancer survival by improving early detection and prevention.
How to participate
This study is open to enrollment. To participate, please contact the study team: (Contact us button below)
ClinicalTrials.gov ID: NCT04970056
(https://clinicaltrials.gov/study/NCT04970056)
- Essai de profilage moléculaire des cancers des voies biliaires L'Essai de Profilage Moléculaire Complet des Cancers Avancés des Voies Biliaires pour une Meilleure Sélection de Traitement (COMPASS-B-MUHC) est un essai prospectif de profilage moléculaire pour les patients atteints de cancers avancés des voies biliaires. Les patients inscrits à l'étude subissent une biopsie avant le début de leur traitement afin de profiler moléculairement leur tumeur (séquençage complet du génome et du transcriptome). Les résultats de ce profilage moléculaire sont communiqués aux patients et à leurs oncologues pour orienter les décisions de traitement par thérapie de précision. En plus des impacts cliniques en temps réel, les données génomiques et transcriptomiques ainsi que les spécimens biologiques de biopsie liquide longitudinaux seront utilisés pour des études de découverte visant à améliorer notre compréhension du développement et de la progression des cancers des voies biliaires.
Comment participer
Cet essai est ouvert aux patients atteints de cancers avancés des voies biliaires (cholangiocarcinome ou cancer de la vésicule biliaire) qui n'ont pas encore commencé leur traitement et qui prévoient de recevoir leur traitement du cancer (y compris la chimiothérapie) au Centre universitaire de santé McGill. ClinicalTrials. gov ID: NCT04318834 (https://clinicaltrials.gov/study/NCT04318834)
Pour les patients recevant un traitement du cancer dans un autre hôpital, ils peuvent être éligibles pour le profilage de la tumeur (séquençage complet du génome et du transcriptome) par le biais de l'un de nos projets du Réseau des centres d’oncologie du marathon de l’espoir. (https://www.marathonofhopecancercentres.ca/)
Pour participer, veuillez contacter l'équipe de l'étude en utilisant le bouton "Nous contacter" ci-dessous. Biliary Tract Cancer Molecular Profiling Trial Comprehensive Molecular Profiling of Advanced Biliary Tract Cancers for Better Treatment Selection (COMPASS-B-MUHC) is a prospective molecular profiling trial for patients with advanced biliary tract cancers. Patients enrolled in the study undergo a biopsy before the start of their treatment to molecularly profile their tumour (whole genome and whole transcriptome sequencing). These molecular profiling results are returned to the patients and their oncologists to guide precision therapy treatment decisions. In addition to real-time clinical impacts, the genomic and transcriptomic data as well as longitudinal liquid biopsy biospecimens will be used for discovery studies to improve our understanding of the development and progression of biliary tract cancers.
How to participate
This trial is open to patients with advanced biliary tract cancers (cholangiocarcinoma or gallbladder cancer) who have not yet started treatment and who intend on receiving their cancer treatment (including chemotherapy) at the McGill University Health Centre. ClinicalTrials. gov ID: NCT04318834 (https://clinicaltrials.gov/study/NCT04318834)
For patients receiving cancer treatment at another hospital, they may be eligible for tumour profiling (whole genome and whole transcriptome sequencing) through one of our Marathon of Hope Cancer Centres Network (MOHCCN) projects. (https://www.marathonofhopecancercentres.ca/)
To participate, please contact the study team.
- L'étude québécoise sur le cancer du pancréas (EQCP) L'Étude québécoise sur le cancer du pancréas (EQCP) a été créée en tant que registre du cancer du pancréas familial avec pour objectif de fournir aux patients une évaluation du risque héréditaire et des tests génétiques au point de soins. L'EQCP a été étendue pour inclure les cancers des voies biliaires et les tumeurs apparentées, tels que les cancers ampullaires et les néoplasmes kystiques précancéreux. Pour mener des études sur la découverte héréditaire et des biomarqueurs, l'étude dispose d'un répertoire de spécimens biologiques avec une biobanque vivante de modèles de tumeurs dérivées de patients. L'EQCP est enregistrée auprès du Réseau de recherche sur le cancer (RRCancer) et accréditée par le Réseau canadien des biobanques de tumeurs (CTRNet).
L'EQCP est intégrée aux cliniques ambulatoires d'oncologie médicale et chirurgicale du Centre du cancer Cedars du Centre universitaire de santé McGill. Grâce à cette stratégie de recherche, l'EQCP a été pionnière dans la mise en place de tests génétiques germinaux de routine avec un retour rapide des résultats aux patients atteints de cancer au Centre universitaire de santé McGill et dans tout le Québec. Au fil des années, l'EQCP s'est étendue pour offrir des opportunités innovantes de traduction en santé de précision et des essais cliniques aux patients.
Comment participer
L'EQCP est ouverte aux inscriptions. Pour participer, veuillez contacter l'équipe de l'étude en utilisant le bouton "Nous contacter" ci-dessous.
ClinicalTrials.gov ID: NCT04970056 The Quebec Pancreas Cancer Study (QPCS) The Quebec Pancreas Cancer Study (QPCS) was established as a familial pancreatic cancer registry with a strategy to provide patients with point-of-care hereditary risk assessment and genetic testing. The QPCS has been expanded to include biliary tract cancers and related tumours, such as ampullary cancers and prem alignant cystic neoplasms. To pursue hereditary and biomarker discovery studies, the study has an accompanying biospecimen repository with a living biobank of patient-derived tumour models. The QPCS is registered with the Réseau de recherche sur le cancer (RRCancer) and accredited by the Canadian Tumor Repository Network (CTRNet).
The QPCS is embedded within the outpatient medical and surgical oncology clinics at the Cedars Cancer Centre of the McGill University Health Centre. Through this research strategy, the QPCS was a pioneer in bringing routine germline genetic testing with rapid return of results to cancer patients at the McGill University Health Centre and across Quebec. Over the years, the QPCS has expanded to bring innovative precision health translational and clinical trial opportunities to patients.
How to participate
The QPCS is open to enrollment. To participate, please contact the study team: (Contact us button below)
ClinicalTrials.gov ID: NCT04104230
(https://clinicaltrials.gov/study/NCT04104230)
- Associate Professor
Rosalind and Morris Goodman Cancer Institute
Departments Oncology and Surgery
Research Institute of the McGill University Health Centre (RI-MUHC)
Faculty of Medicine and Health Sciences
McGill University
- 2021 Clinical Research Scholar (Senior), Fonds de recherche du Québec - Santé
- 2021 Michal & Renata Hornstein Career Award for Surgical Excellence, McGill University1.
- 2016 Clinical Research Scholar (Junior 2), Fonds de recherche du Québec – Santé
- 2012 Clinical Research Scholar (Junior 1), Fonds de recherche du Québec – Santé
Our team
- Adedline Cuggia Conseiller.ère en génétique et coordonateur.trice de recherche Genetic Counsellor & Research Coordinator
- Ruomeng Fang Étudiant.e à la maîtrise MSc Student
- Jennifer Gardner Coordonateur.trice de recherche Research Coordinator
- Alicia Gomez Mendez Coordonateur.trice de laboratoire Lab Manager/Supervisor
- Charlotte Hadjadj Coordonateur.trice de recherche Research Coordinator
- Fatima Inigo Associé.e de recherche Research Assistant/Associate
- Dinghon Qiu Associé.e de recherche Research Assistant/Associate
- Joan Miguel Romero Étudiant.e au doctorat PhD Student
- Yifan Wang Étudiant.e au doctorat PhD Student
Major discoveries
PublicationsResearch Partners
Get in touch
1001 Boul. Décarie
Montreal, Quebec H4A 3J1
Office: 611
Lab: 611
T. 514-934-1934, ext. 36306
T.
F. 514-843-1434
george.zogopoulos@mcgill.ca
Contact us for any questions about
our recruitment process
Rosalind & Morris Goodman Cancer Institute all rights reserved • Privacy policy • Accessibility
Website by Riposte
